vs
Side-by-side financial comparison of BRINKS CO (BCO) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.4B, roughly 1.7× BRINKS CO). Zoetis runs the higher net margin — 25.3% vs 4.9%, a 20.3% gap on every dollar of revenue. On growth, BRINKS CO posted the faster year-over-year revenue change (9.1% vs 3.0%). Over the past eight quarters, BRINKS CO's revenue compounded faster (5.6% CAGR vs 4.4%).
The Brink's Company is an American cash handling company, headquartered in Richmond, Virginia. Its operations include cash-in-transit, ATM replenishment & maintenance, and cash management & payment services, such as vault outsourcing, money processing, intelligent safe services, and international transportation of valuables.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
BCO vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $2.4B |
| Net Profit | $68.1M | $603.0M |
| Gross Margin | 27.7% | 70.2% |
| Operating Margin | 13.1% | 31.9% |
| Net Margin | 4.9% | 25.3% |
| Revenue YoY | 9.1% | 3.0% |
| Net Profit YoY | 76.9% | 3.8% |
| EPS (diluted) | $1.62 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.2B | $2.2B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $1.3B | $2.4B | ||
| Q1 24 | $1.2B | $2.2B |
| Q4 25 | $68.1M | $603.0M | ||
| Q3 25 | $36.3M | $721.0M | ||
| Q2 25 | $43.7M | $718.0M | ||
| Q1 25 | $51.6M | $631.0M | ||
| Q4 24 | $38.5M | $581.0M | ||
| Q3 24 | $28.9M | $682.0M | ||
| Q2 24 | $46.2M | $624.0M | ||
| Q1 24 | $49.3M | $599.0M |
| Q4 25 | 27.7% | 70.2% | ||
| Q3 25 | 25.8% | 71.5% | ||
| Q2 25 | 24.9% | 73.6% | ||
| Q1 25 | 24.6% | 72.0% | ||
| Q4 24 | 26.1% | 69.5% | ||
| Q3 24 | 25.0% | 70.6% | ||
| Q2 24 | 25.2% | 71.7% | ||
| Q1 24 | 25.0% | 70.6% |
| Q4 25 | 13.1% | 31.9% | ||
| Q3 25 | 11.4% | 37.0% | ||
| Q2 25 | 10.3% | 36.7% | ||
| Q1 25 | 9.6% | 36.5% | ||
| Q4 24 | 8.3% | 31.6% | ||
| Q3 24 | 8.9% | 36.6% | ||
| Q2 24 | 9.3% | 33.0% | ||
| Q1 24 | 9.8% | 34.1% |
| Q4 25 | 4.9% | 25.3% | ||
| Q3 25 | 2.7% | 30.0% | ||
| Q2 25 | 3.4% | 29.2% | ||
| Q1 25 | 4.1% | 28.4% | ||
| Q4 24 | 3.0% | 25.1% | ||
| Q3 24 | 2.3% | 28.6% | ||
| Q2 24 | 3.7% | 26.4% | ||
| Q1 24 | 4.0% | 27.4% |
| Q4 25 | $1.62 | $1.37 | ||
| Q3 25 | $0.86 | $1.63 | ||
| Q2 25 | $1.03 | $1.61 | ||
| Q1 25 | $1.18 | $1.41 | ||
| Q4 24 | $0.87 | $1.29 | ||
| Q3 24 | $0.65 | $1.50 | ||
| Q2 24 | $1.02 | $1.37 | ||
| Q1 24 | $1.09 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | — |
| Total DebtLower is stronger | $4.0B | — |
| Stockholders' EquityBook value | $277.7M | $3.3B |
| Total Assets | $7.3B | $15.5B |
| Debt / EquityLower = less leverage | 14.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.4B | $1.4B | ||
| Q1 25 | $1.2B | $1.7B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.2B | $1.7B | ||
| Q2 24 | $1.2B | $1.6B | ||
| Q1 24 | $1.1B | $2.0B |
| Q4 25 | $4.0B | — | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $3.9B | — | ||
| Q1 25 | $3.7B | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.7B | — | ||
| Q2 24 | $3.6B | — | ||
| Q1 24 | $3.4B | — |
| Q4 25 | $277.7M | $3.3B | ||
| Q3 25 | $268.5M | $5.4B | ||
| Q2 25 | $254.6M | $5.0B | ||
| Q1 25 | $205.8M | $4.7B | ||
| Q4 24 | $184.9M | $4.8B | ||
| Q3 24 | $277.1M | $5.2B | ||
| Q2 24 | $320.5M | $5.0B | ||
| Q1 24 | $396.4M | $5.1B |
| Q4 25 | $7.3B | $15.5B | ||
| Q3 25 | $7.0B | $15.2B | ||
| Q2 25 | $7.1B | $14.5B | ||
| Q1 25 | $6.6B | $14.1B | ||
| Q4 24 | $6.6B | $14.2B | ||
| Q3 24 | $6.7B | $14.4B | ||
| Q2 24 | $6.6B | $14.2B | ||
| Q1 24 | $6.7B | $14.3B |
| Q4 25 | 14.31× | — | ||
| Q3 25 | 14.05× | — | ||
| Q2 25 | 15.48× | — | ||
| Q1 25 | 18.19× | — | ||
| Q4 24 | 20.26× | — | ||
| Q3 24 | 13.39× | — | ||
| Q2 24 | 11.26× | — | ||
| Q1 24 | 8.67× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | 3.5% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $893.0M | ||
| Q3 25 | $122.1M | $938.0M | ||
| Q2 25 | — | $486.0M | ||
| Q1 25 | $-60.2M | $587.0M | ||
| Q4 24 | $369.8M | $905.0M | ||
| Q3 24 | $58.4M | $951.0M | ||
| Q2 24 | $-66.1M | $502.0M | ||
| Q1 24 | $63.9M | $595.0M |
| Q4 25 | — | $732.0M | ||
| Q3 25 | $77.4M | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | $-119.1M | $438.0M | ||
| Q4 24 | $307.2M | $689.0M | ||
| Q3 24 | $7.4M | $784.0M | ||
| Q2 24 | $-122.8M | $370.0M | ||
| Q1 24 | $11.7M | $455.0M |
| Q4 25 | — | 30.7% | ||
| Q3 25 | 5.8% | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | -9.6% | 19.7% | ||
| Q4 24 | 24.3% | 29.7% | ||
| Q3 24 | 0.6% | 32.8% | ||
| Q2 24 | -9.8% | 15.7% | ||
| Q1 24 | 0.9% | 20.8% |
| Q4 25 | 3.5% | 6.7% | ||
| Q3 25 | 3.3% | 5.5% | ||
| Q2 25 | 4.0% | 7.2% | ||
| Q1 25 | 4.7% | 6.7% | ||
| Q4 24 | 5.0% | 9.3% | ||
| Q3 24 | 4.1% | 7.0% | ||
| Q2 24 | 4.5% | 5.6% | ||
| Q1 24 | 4.2% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 3.36× | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | -1.17× | 0.93× | ||
| Q4 24 | 9.61× | 1.56× | ||
| Q3 24 | 2.02× | 1.39× | ||
| Q2 24 | -1.43× | 0.80× | ||
| Q1 24 | 1.30× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCO
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
